{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:44:45Z","timestamp":1793061885689,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EO1502"],"award-info":[{"award-number":["01EO1502"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00134-021-06609-6","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T13:02:42Z","timestamp":1643720562000},"page":"311-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Effect of therapeutic drug monitoring-based dose optimization of piperacillin\/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-6131","authenticated-orcid":false,"given":"Stefan","family":"Hagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedhelm","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Bracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Annecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nierhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Jarczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Weismann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kiehntopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Neugebauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the TARGET Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Braune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Motsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Pinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schlattmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ameln-Mayerhofer von","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schappacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anka","family":"R\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kurlbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"H\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gr\u00fcndling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Angermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Deja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Chkirni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"6609_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06506-y","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. https:\/\/doi.org\/10.1007\/s00134-021-06506-y","journal-title":"Intensive Care Med"},{"key":"6609_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"6609_CR3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M et al (2014) DALI: defining antibiotic levels in intensive care unit patients: are current\u2014lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072\u20131083. https:\/\/doi.org\/10.1093\/cid\/ciu027","journal-title":"Clin Infect Dis"},{"key":"6609_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1086\/510590","volume":"44","author":"TP Lodise","year":"2007","unstructured":"Lodise TP, Lomaestro B, Drusano GL (2007) Piperacillin\u2013tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44:357\u2013363. https:\/\/doi.org\/10.1086\/510590","journal-title":"Clin Infect Dis"},{"key":"6609_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02571-19","author":"E Tannous","year":"2020","unstructured":"Tannous E, Lipman S, Tonna A et al (2020) Time above the MIC of piperacillin\u2013tazobactam as a predictor of outcome in Pseudomonas aeruginosa bacteraemia. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02571-19","journal-title":"Antimicrob Agents Chemother"},{"key":"6609_CR6","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre P-F, Dugernier T et al (2010) Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126. https:\/\/doi.org\/10.1186\/cc9091","journal-title":"Crit Care"},{"key":"6609_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv201","author":"A Huttner","year":"2015","unstructured":"Huttner A, Harbarth S, Hope WW et al (2015) Therapeutic drug monitoring of the \u03b2-lactam antibiotics: what is the evidence and which patients should we be using it for?: Figure 1. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dkv201","journal-title":"J Antimicrob Chemother"},{"key":"6609_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz M-H, Davis JS et al (2016) Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med 194:681\u2013691. https:\/\/doi.org\/10.1164\/rccm.201601-0024OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6609_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcrc.2018.08.026","volume":"48","author":"C Carri\u00e9","year":"2018","unstructured":"Carri\u00e9 C, Legeron R, Petit L et al (2018) Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin\u2013tazobactam administered by continuous infusion. J Crit Care 48:66\u201371. https:\/\/doi.org\/10.1016\/j.jcrc.2018.08.026","journal-title":"J Crit Care"},{"key":"6609_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jcrc.2019.04.013","volume":"52","author":"SAM Dhaese","year":"2019","unstructured":"Dhaese SAM, Thooft ADJ, Farkas A et al (2019) Early target attainment of continuous infusion piperacillin\/tazobactam and meropenem in critically ill patients: a prospective observational study. J Crit Care 52:75\u201379. https:\/\/doi.org\/10.1016\/j.jcrc.2019.04.013","journal-title":"J Crit Care"},{"key":"6609_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar J-WC, Bassetti M et al (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med 46:1127\u20131153. https:\/\/doi.org\/10.1007\/s00134-020-06050-1","journal-title":"Intensive Care Med"},{"key":"6609_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/00007691-199902000-00010","volume":"21","author":"NA van Lent-Evers","year":"1999","unstructured":"van Lent-Evers NA, Math\u00f4t RA, Geus WP et al (1999) Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 21:63\u201373. https:\/\/doi.org\/10.1097\/00007691-199902000-00010","journal-title":"Ther Drug Monit"},{"key":"6609_CR13","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP et al (2020) Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 71:1361\u20131364. https:\/\/doi.org\/10.1093\/cid\/ciaa303","journal-title":"Clin Infect Dis"},{"key":"6609_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","volume":"40","author":"JJ De Waele","year":"2014","unstructured":"De Waele JJ, Carrette S, Carlier M et al (2014) Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40:380\u2013387. https:\/\/doi.org\/10.1007\/s00134-013-3187-2","journal-title":"Intensive Care Med"},{"key":"6609_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.clinthera.2017.06.008","volume":"39","author":"AS Machado","year":"2017","unstructured":"Machado AS, Oliveira MS, Sanches C et al (2017) Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients. Clin Ther 39:1649-1657.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.008","journal-title":"Clin Ther"},{"key":"6609_CR16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s15010-019-01352-z","volume":"47","author":"DC Richter","year":"2019","unstructured":"Richter DC, Frey O, R\u00f6hr A et al (2019) Therapeutic drug monitoring-guided continuous infusion of piperacillin\/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection 47:1001\u20131011. https:\/\/doi.org\/10.1007\/s15010-019-01352-z","journal-title":"Infection"},{"key":"6609_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","volume":"36","author":"JA Roberts","year":"2010","unstructured":"Roberts JA, Ulldemolins M, Roberts MS et al (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332\u2013339. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.06.008","journal-title":"Int J Antimicrob Agents"},{"key":"6609_CR18","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/jac\/dkv123","volume":"70","author":"FB Sime","year":"2015","unstructured":"Sime FB, Roberts MS, Tiong IS et al (2015) Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. J Antimicrob Chemother 70:2369\u20132375. https:\/\/doi.org\/10.1093\/jac\/dkv123","journal-title":"J Antimicrob Chemother"},{"key":"6609_CR19","doi-asserted-by":"publisher","first-page":"Doc14","DOI":"10.3205\/000103","volume":"8","author":"K Reinhart","year":"2010","unstructured":"Reinhart K, Brunkhorst FM, Bone H-G et al (2010) Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplin\u00e4re Vereinigung f\u00fcr Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci 8:Doc14. https:\/\/doi.org\/10.3205\/000103","journal-title":"Ger Med Sci"},{"key":"6609_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s13063-019-3437-x","volume":"20","author":"S Hagel","year":"2019","unstructured":"Hagel S, Fiedler S, Hohn A et al (2019) Therapeutic drug monitoring-based dose optimisation of piperacillin\/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial. Trials 20:330. https:\/\/doi.org\/10.1186\/s13063-019-3437-x","journal-title":"Trials"},{"key":"6609_CR21","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s001340100909","volume":"27","author":"N Bergeron","year":"2001","unstructured":"Bergeron N, Dubois MJ, Dumont M et al (2001) Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med 27:859\u2013864. https:\/\/doi.org\/10.1007\/s001340100909","journal-title":"Intensive Care Med"},{"key":"6609_CR22","unstructured":"European Medicines Agency (2012) Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples, EMA\/INS\/GCP\/532137\/2010"},{"key":"6609_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s001340050931","volume":"25","author":"R Moreno","year":"1999","unstructured":"Moreno R, Vincent JL, Matos R et al (1999) The use of maximum SOFA score to quantify organ dysfunction\/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med 25:686\u2013696. https:\/\/doi.org\/10.1007\/s001340050931","journal-title":"Intensive Care Med"},{"key":"6609_CR24","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1001\/jama.2012.5833","volume":"307","author":"FM Brunkhorst","year":"2012","unstructured":"Brunkhorst FM, Oppert M, Marx G et al (2012) Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307:2390\u20132399. https:\/\/doi.org\/10.1001\/jama.2012.5833","journal-title":"JAMA"},{"key":"6609_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW, Muller AE, Canton R et al (2018) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73:564\u2013568. https:\/\/doi.org\/10.1093\/jac\/dkx427","journal-title":"J Antimicrob Chemother"},{"key":"6609_CR26","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/jac\/dkx541","volume":"73","author":"TW Felton","year":"2018","unstructured":"Felton TW, Ogungbenro K, Boselli E et al (2018) Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. J Antimicrob Chemother 73:1340\u20131347. https:\/\/doi.org\/10.1093\/jac\/dkx541","journal-title":"J Antimicrob Chemother"}],"updated-by":[{"DOI":"10.1007\/s00134-022-06668-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000}}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-021-06609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-021-06609-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-021-06609-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T02:05:09Z","timestamp":1645581909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-021-06609-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["6609"],"URL":"https:\/\/doi.org\/10.1007\/s00134-021-06609-6","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"12 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH report grants from the Federal Ministry of Education and Research (BMBF), lecture fees from Pfizer, MSD, InfectoPharm, Advanz and Philips, support for attending meetings from Pfizer and Advanz. AB reports lecture fees from MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Fresenius Medical Care (FMC), Labor Volkmann (Karlsruhe). TB reports lecture fees from CSL Behring GmbH, Sch\u00f6chl medical education GmbH, Biotest AG, Baxter Deutschland GmbH, Boehringer Ingelheim Pharma GmbH, Astellas Pharma GmbH, B. Braun Melsungen AG, MSD Sharp & Dohme GmbH, support for participation in a Data Safety and Monitoring Board for Baxter Deutschland GmbH and and research funding from Deutsche Forschungsgemeinschaft (DFG), Dietmar Hopp Stiftung, Stiftung Universit\u00e4tsmedizin Essen. Heidelberger Stiftung Chirurgie, Innovationsfonds des Gemeinsamen Bundesausschusses (G-BA). SN reports grants from the Center for Sepsis Control and Care (CSCC) by the Ministry of Education and Research (BMBF), Grant-no. 01EO1502. SK reports grants from Ambu, Daiichi Sankyo, ETView Ltd, Fisher & Paykel, Pfizer and Xenios, consulting fees from Bayer, Fresenius, Gilead, MSD and Pfizer, lecture fees from Astra, C.R.Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips and Zoll. MW reports lecture fees from MSD, Gilead, Shionogi, Pfizer, support for participation in a Data Safety and Monitoring Board for MSD, Gilead, Shionogi, Eumedica, Biotest. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The trial was approved by the relevant ethics committees in all study sites.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients or from their surrogates.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the manuscript for submission.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}